Lowering LDL… But Losing Muscle? The Data You Haven’t Seen

Mutzel observed that many people are doing dedicated grip work (dead hangs, farmer carries) which he called great exercises, but he emphasized that focusing on heavy compound lifts like deadlifts and rows—and especially pull-ups—will develop grip strength while building total body muscle. He tied this back to the statin study: if grip strength is a marker of whole-body strength and statin users lose it faster, then anything that raises baseline strength and slows age-related decline is protective. He advocated that instead of just isolating grip, one should train the whole system, because when you exercise your entire body you improve grip strength as well.

Mutzel promoted creatine heavily in the context of the muscle-loss discussion, arguing that if statins threaten muscle mass, strategies that build and protect muscle become even more critical. He highlighted data showing creatine can mitigate cognitive deficits following a bad night's sleep, improve mood, and help with age-related dehydration. He attributed low dietary creatine intake to widespread red meat avoidance due to fear of saturated fat and cholesterol. He then contrasted Chinese-sourced creatine, which carries higher levels of two contaminants, with German Creapure, which he sells through his company Myoscience. He offered a discount code and directed listeners to the link in the description. The overall message was that creatine is a safe, evidence-based tool to bolster neuromuscular and cognitive resilience.

Mutzel advised that if you are already strong, metabolically healthy, and following a whole-foods lifestyle, you should question the need for a statin. He suggested printing the paper and bringing it to your doctor, asking directly: are you aware of this data? He underscored that muscle strength and mass are independently protective against all-cause mortality, and that sacrificing them for lower LDL may not be a good trade-off. He shared the anecdote of the 33-year-old woman to illustrate how even young, lean hyper-responders are being targeted, despite zero outcome evidence in females. The implicit message: the standard-of-care prescription of statins for elevated LDL alone needs to be challenged with new evidence, and patients can be the catalyst.

Mike Mutzel presented this new paper to argue that patients and clinicians are often unaware of the unintended consequences of statins. He pointed out that the 73% decline in appendicular lean mass is a staggering number that would make most people reconsider the risk-benefit trade-off. The study employed grip strength as a proxy for whole-body strength, showing that continuous statin users experienced a steeper decline over time compared to never users. Mutzel emphasized that the harm extends beyond subjective myalgia: it’s a measurable loss of muscle quantity and function. He contextualised this by noting that muscle is vital for metabolic health, post-meal glucose disposal, and overall vitality. He urged listeners to consider whether a monomaniacal focus on LDL cholesterol is blinding them to harms that could undermine quality of life and longevity. The paper’s authors also cited preclinical data linking statins to mitochondrial dysfunction, impaired protein synthesis, and preferential loss of type II fast-twitch fibers, all of which would explain the observed functional decline.

Mutzel argued that the medical community has become fixated on LDL reduction while ignoring how statins disrupt protective hormonal pathways. He noted that many people with obesity or type 2 diabetes already have suppressed GLP-1 secretion, and yet they may be prescribed a statin that further lowers it. This creates a pharmacological tug-of-war: one drug tries to raise GLP-1 for metabolic control, while another inadvertently lowers it. He used this example to reinforce the need for a more holistic risk-benefit calculus, especially when statins also impair muscle, which itself is a major site of glucose disposal. The GLP-1 suppression, combined with muscle loss and elevated diabetes risk, paints a picture of metabolic sabotage that is rarely discussed in the clinic.

Mutzel shared the story of someone close to him—a 33-year-old active female who exercises frequently and eats well but had elevated LDL due to a lean mass hyper-responder phenotype. Her doctor was aggressively pushing a statin. Mutzel stressed that there has never been any research in women showing that lowering LDL cholesterol improves hard outcomes, making this recommendation scientifically unjustified. He used the example to illustrate that the push for statins extends even to young, healthy people who may be harmed far more than helped, especially when considering the newly documented risks of muscle wasting and metabolic dysfunction.

Mutzel noted that many professional and recreational athletes he has known were told their lipid levels were high and were prescribed a statin, only to experience a demonstrable drop in strength and exercise capacity. Football linemen, who may weigh over 320 lbs and have high body fat, often have elevated lipids but learn to refuse statins because they hinder performance. This aligns mechanistically with statins' inhibition of CoQ10 synthesis, which is critical for mitochondrial ATP production in muscle. The fact that athletes intuitively recognise this harm and avoid the drugs, despite medical advice, underscores the need to take the muscle toxicity of statins seriously. He used this anecdote to argue that the muscle decline seen in epidemiological studies is not just a statistical artefact but a tangible effect noticed by those who push their bodies.